BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 15621843)

  • 1. Cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) plus rituximab is effective and well tolerated in poor performance status elderly patients with non-Hodgkin's lymphoma.
    Visani G; Guiducci B; D'Adamo F; Mele A; Nicolini G; Leopardi G; Sparaventi G; Barulli S; Malerba L; Isidori A; Malagola M; Piccaluga PP
    Leuk Lymphoma; 2005 Mar; 46(3):477-9. PubMed ID: 15621843
    [No Abstract]   [Full Text] [Related]  

  • 2. Incidence of interstitial pneumonitis in non-Hodgkin's lymphoma patients receiving immunochemotherapy with pegylated liposomal doxorubicin and rituximab.
    Zhou T; Shen Q; Peng H; Chao T; Zhang L; Huang L; Yang K; Thapa S; Yu S; Jiang Y
    Ann Hematol; 2018 Jan; 97(1):141-147. PubMed ID: 29086009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Non-pegylated liposomal doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab for the treatment of non-Hodgkin's lymphoma: study of 26 patients].
    Moreno M; Sancho JM; Gardella S; Coll R; GarcĂ­a O; Gallardo D; Ribera JM
    Med Clin (Barc); 2010 Jan; 134(2):72-5. PubMed ID: 19913261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab plus CHOP as an initial chemotherapy for patients with disseminated MALT lymphoma.
    Ennishi D; Yokoyama M; Mishima Y; Watanabe C; Terui Y; Takahashi S; Takeuchi K; Ikeda K; Tanimoto M; Hatake K
    Leuk Lymphoma; 2007 Nov; 48(11):2241-3. PubMed ID: 17990181
    [No Abstract]   [Full Text] [Related]  

  • 5. Precore mutant hepatitis B reactivation after treatment with CHOP-rituximab.
    Zell JA; Yoon EJ; Ignatius Ou SH; Hoefs JC; Chang JC
    Anticancer Drugs; 2005 Jan; 16(1):83-5. PubMed ID: 15613909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab.
    Lim KH; Yoon HI; Kang YA; Lee KW; Kim JH; Bang SM; Lee JH; Lee CT; Lee JS
    Korean J Intern Med; 2010 Mar; 25(1):86-92. PubMed ID: 20195409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Skin lesions in a female patient with non-Hodgkin lymphoma].
    Ducasse VO; Pintado JA; Gordon MM; Oyonarte MC
    Enferm Infecc Microbiol Clin; 2007; 25(7):489-90. PubMed ID: 17692217
    [No Abstract]   [Full Text] [Related]  

  • 8. Three cases of Pneumocystis jirovecii pneumonia (PCP) during first-line treatment with rituximab in combination with CHOP-14 for aggressive B-cell non-Hodgkin's lymphoma.
    Venhuizen AC; Hustinx WN; van Houte AJ; Veth G; van der Griend R
    Eur J Haematol; 2008 Mar; 80(3):275-6. PubMed ID: 18005387
    [No Abstract]   [Full Text] [Related]  

  • 9. Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma.
    Kilickap S; Yavuz B; Aksoy S; Sahiner L; Dincer M; Harputluoglu H; Erman M; Aytemir K; Tokgozoglu L; Barista I
    Med Oncol; 2008; 25(4):437-42. PubMed ID: 18415035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Full-dose chemotherapy for non-Hodgkin's lymphoma in the elderly. Dutch Hematology-Oncology in Adults Study Group.
    Sonneveld P; Hop W; Mulder AH; Michiels JJ; Blijham G; van de Lelie J; Raemakers JW; Nieuwenhuis K; van der Heul C
    Semin Hematol; 1994 Apr; 31(2 Suppl 3):9-12. PubMed ID: 8073309
    [No Abstract]   [Full Text] [Related]  

  • 11. Sarcoid-like reaction in the spleen following chemotherapy for non-Hodgkin's lymphoma.
    Reilly TB; Schuster DM; Starsiak MD; Kost CB; Halkar RK
    Clin Nucl Med; 2007 Jul; 32(7):569-71. PubMed ID: 17581351
    [No Abstract]   [Full Text] [Related]  

  • 12. [Treatment of elderly patients with non-Hodgkin's lymphoma].
    Titorenko IB; Kriachok IA
    Lik Sprava; 2011; (5-6):79-85. PubMed ID: 22606896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma.
    Derenzini E; Stefoni V; Pellegrini C; Fina MP; Broccoli A; Venturini F; Gandolfi L; Pileri SA; Martelli M; Petti MC; Perrotti A; De Renzo A; Zaja F; Baccarani M; Zinzani PL
    Leuk Lymphoma; 2009 Nov; 50(11):1824-9. PubMed ID: 19814687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Supportive care for patients with non-Hodgkin lymphoma receiving R-CHOP chemotherapy].
    Kato H
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():636-41. PubMed ID: 25831838
    [No Abstract]   [Full Text] [Related]  

  • 15. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma.
    Coiffier B
    Tumori; 2002; 88(1 Suppl 1):S26-8. PubMed ID: 11989916
    [No Abstract]   [Full Text] [Related]  

  • 16. Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.
    Case DC; Desch CE; Kalman LA; Vongkovit P; Mena RR; Fridman M; Allen B
    Clin Lymphoma Myeloma; 2007 Mar; 7(5):354-60. PubMed ID: 17562245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of front-line chemotherapy for aggressive non-Hodgkin's lymphoma using the CAP-BOP regimens. The Nebraska Lymphoma Study Group.
    Vose JM; Anderson JR; Bierman PJ; Bast M; Weisenburger D; Chan WC; Bishop MR; Armitage JO
    Semin Hematol; 1994 Apr; 31(2 Suppl 3):4-8. PubMed ID: 7521065
    [No Abstract]   [Full Text] [Related]  

  • 18. Chemoradiotherapy for localized non-Hodgkin's lymphoma.
    Cosset JM
    N Engl J Med; 1998 Jul; 339(1):44-5. PubMed ID: 9647881
    [No Abstract]   [Full Text] [Related]  

  • 19. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma.
    Sparano JA; Lee JY; Kaplan LD; Levine AM; Ramos JC; Ambinder RF; Wachsman W; Aboulafia D; Noy A; Henry DH; Von Roenn J; Dezube BJ; Remick SC; Shah MH; Leichman L; Ratner L; Cesarman E; Chadburn A; Mitsuyasu R;
    Blood; 2010 Apr; 115(15):3008-16. PubMed ID: 20023215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium.
    Hainsworth JD; Flinn IW; Spigel DR; Clark BL; Griner PL; Vazquez ER; Doss HH; Shipley D; Franco LA; Burris HA; Greco FA;
    Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):44-50. PubMed ID: 20223728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.